Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

Published:2013-07-19 Issue:10 Volume:12 Page:2031-2042
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Herter Sylvia,Herting Frank,Mundigl Olaf,Waldhauer Inja,Weinzierl Tina,Fauti Tanja,Muth Gunter,Ziegler-Landesberger Doris,Van Puijenbroek Erwin,Lang Sabine,Duong Minh Ngoc,Reslan Lina,Gerdes Christian A.,Friess Thomas,Baer Ute,Burtscher Helmut,Weidner Michael,Dumontet Charles,Umana Pablo,Niederfellner Gerhard,Bacac Marina,Klein Christian

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 294 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted therapies in SLE;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study;Virology Journal;2024-09-09

3. Germinal center B-cell subgroups in the tumor microenvironment cannot be overlooked: their involvement in prognosis, immunotherapy response, and treatment resistance in head and neck squamous carcinoma;Heliyon;2024-09

4. Rational design of environmentally responsive antibodies with pH-sensing synthetic amino acids;Scientific Reports;2024-08-21

5. Impact of leukemia-associated macrophages on the progression and therapy response of chronic lymphocytic leukemia;Leukemia Research;2024-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP